ReNewVax has been featured in this autumn’s edition of Drug Target Review, sharing insights into our quest for a universal pneumococcal vaccine.
‘Why innovation is the key to unlocking a universal pneumococcal vaccine’, details how the principle of reverse vaccinology – employing rational design in lieu of the classical hypothesis-led approach to vaccine development – will be pivotal in the creation of new vaccines that the developing world so badly needs.
In the piece, we discuss the pressing issues facing the healthcare community in terms of vaccines, such as the need to make the case for comprehensive use of existing vaccines to tackle things like current measles cases in London which threaten to cause huge outbreaks if vaccination rates do not improve.
We also discuss the challenges involved with developing bacterial vaccines, from the impracticality of developing vaccines against individual pathogens, to the expensive manufacturing costs which are beyond the reach of the low- and middle-income countries that need them most.
To read the feature, download this edition of Drug Target Review: https://www.drugtargetreview.com/article/111495/drug-target-review-issue-3-2023/